2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Colorectal Neoplasms
8
Colonic Polyps
3
Lung Neoplasms
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Precancerous Conditions
1
Melanoma
1
Disease
1
Breast Neoplasms
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
135
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
67
fludarabine phosphate
61
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Cisplatin
36
CTLA-4 Antigen
36
Carboplatin
35
cobimetinib
34
Specimen Handling
34
Magnetic Resonance Spectroscopy
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Diagnosis, Computer-Assisted
×
Clear all
NCT06221397
2026-03-16
LEGIT_MC_EVCDA
AI Labs Group S.L
Completed
105 enrolled
15 charts